Nuvalent ( NASDAQ:NUVL ) , a clinical-stage biotechnology company developing therapies for cancers driven by kinase mutations, released its second quarter 2025 earnings results on August 7, 2025. There was no product revenue, consistent with expectations for a pre-commercial biotech.

Zidesamtinib achieves a 51% ORR and 93% 12- and 18-month durability in patients with one prior ROS1 TKI. Intracranial ORR is 85% in patients previously treated with crizotinib, including 54% complete responses.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. analyst Ed Arce initiated coverage on MetaVia MTVA with a Buy rating and announced a ...

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Nuvalent Inc NUVL shares are trading lower by 6.56% to $104.81 during Tuesday's session after the company priced a $500 million upsized public offering of 5 million common shares at $100 per share. Nuvalent says the offering is expected to close on September 18, pending the satisfaction of ...

Companies In The News Are: INTC, BA, NUVL, AA.